用于治疗性抗体开发的抗体工程

Antibody engineering for the development of therapeutic antibodies.

作者信息

Kim Sang Jick, Park Youngwoo, Hong Hyo Jeong

机构信息

Laboratory of Antibody Engineering, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-333, Korea.

出版信息

Mol Cells. 2005 Aug 31;20(1):17-29.

PMID:16258237

Abstract

Therapeutic antibodies represent one of the fastest growing areas of the pharmaceutical industry. There are currently 19 monoclonal antibodies in the market that have been approved by the FDA and over 150 in clinical developments. Driven by innovation and technological developments, therapeutic antibodies are the second largest biopharmaceutical product category after vaccines. Antibodies have been engineered by a variety of methods to suit a particular therapeutic use. This review describes the structural and functional characteristics of antibody and the antibody engineering for the generation and optimization of therapeutic antibodies.

摘要

治疗性抗体是制药行业中发展最快的领域之一。目前市场上有19种单克隆抗体已获美国食品药品监督管理局（FDA）批准，还有150多种正处于临床开发阶段。在创新和技术发展的推动下，治疗性抗体是仅次于疫苗的第二大生物制药产品类别。人们已通过多种方法对抗体进行改造，以适用于特定的治疗用途。本文综述了抗体的结构和功能特性，以及用于生成和优化治疗性抗体的抗体工程。